On the other hand, a promising response rate of 37.0 % (95 % CI 23.2–52.5) and disease control rate of 82.6 % (95 % CI 68.2–92.2) were reported in a phase II trial exploring paclitaxel (weekly administration) + trastuzumab (JFMC45-1102 trial) for 46 evaluable patients with HER2-positive gastric cancer who were pretreated with a regimen that did not contain trastuzumab [58]. The gene discussed is ERBB2; the disease is gastric cancer.